Please wait...


Generic Name: aflibercept ophthalmic (a FLIB er sept off THAL mik)
Brand Names: Eylea
Eylea (aflibercept) is used to treat with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Includes Eylea side effects, interactions and indications.
  • Prescription Settings

Prices and coupons of Eylea

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code

Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Eylea (aflibercept) is made from a human antibody fragment. It works by keeping new blood vessels from forming under the retina (a sensory membrane that lines the inside of the eye). In people with a certain type of eye disease, new blood vessels grow under the retina where they leak blood and fluid. This is known as the "wet form" of macular degeneration. Eylea is used to treat wet age-related macular degeneration. It is also used to treat swelling in the retina caused by a blockage in the blood vessels. Learn more

Eylea Side Effects

Eylea Side Effects

Note: This document contains side effect information about aflibercept ophthalmic. Some of the dosage forms listed on this page may not apply to the brand name Eylea.

In Summary

More frequent side effects include: increased intraocular pressure. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to aflibercept ophthalmic: intraocular solution

Along with its needed effects, aflibercept ophthalmic (the active ingredient contained in Eylea) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking aflibercept ophthalmic:

More common

  • Blindness
  • bloody eye
  • blurred vision
  • eye or eyelid redness
  • eye pain
  • seeing flashes, sparks of light, or a veil or curtain
  • seeing floating spots before the eyes
  • vision changes

Less common

  • Bleeding or pain at the injection site
  • swelling of the eyelid


  • Fast heartbeat
  • fever
  • headache
  • hives, itching, rash, or skin redness
  • hoarseness
  • joint pain, stiffness, or swelling
  • swelling of the face, lips, hands, or feet
  • troubled breathing or swallowing

Incidence not known

  • Pain in the chest, groin, or legs, especially the calves
  • severe, sudden headache
  • slurred speech
  • sudden loss of coordination
  • sudden, severe weakness or numbness in the arm or leg
  • sudden, unexplained shortness of breath

Some side effects of aflibercept ophthalmic may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

  • Feeling like something is in the eye
  • watery eyes

For Healthcare Professionals

Applies to aflibercept ophthalmic: intravitreal solution


The more commonly reported adverse reactions have included conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and increased intraocular pressure.


Very common (10% or more): Conjunctival hemorrhage (28%), eye pain (13%),

Common (1% to 10%): Cataract, vitreous floaters, corneal erosion, intraocular pressure increased, conjunctival hyperemia, ocular hyperemia, vitreous detachment, foreign body sensation in eyes, lacrimation increased, vision blurred, intraocular inflammation, retinal pigment epithelium tear, injection site hemorrhage, eyelid edema, corneal edema, retinal degeneration, cataract, cataract nuclear, cataract subcapsular, corneal abrasion, intraocular pressure increased, vitreous floaters

Uncommon (0.1% to 1%): Retinal detachment, retinal tear, endophthalmitis injection site pain, traumatic cataract


Common (1% to 10%): Injection site pain


Intravitreal use of VEGF inhibitors has been associated with a potential risk of arterial thromboembolic events (ATEs) defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including death of unknown cause). In wet age-related macular degeneration (AMD) studies, 1.8% (n=32/1824) and 1.5% (n=9/595) of patients treated with this drug or ranibizumab, respectively, experienced an ATE in the first 52 weeks and 3.3% and 3.2% through 96 weeks, respectively. In the diabetic macular edema (DME) studies, ATEs were reported at incidences of 3.3% (n=19/578) and 2.8% (n=8/287) through week 52, and 6.4% (n=37/578) and 4.2% (n=12/287) through week 100, in patients receiving 2 different dosing regimens of this drug or macular laser photocoagulation (after the first 24 weeks, all patients could receive drug or laser treatment). No ATEs have been reported in the first 6 months of the retinal vein occlusion (RVO) studies.

Common (1% to 10%): Arterial thromboembolic events


Uncommon (0.1% to 1%): Hypersensitivity

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Eylea